About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
LLY - Eli Lilly and Compan...| Previous Close | $198.48 | Open | $198.77 |
| Volume | 5.33M | Market Cap | 182.487B |
| Yield | 1.54 % | Last Dividend | $2.94 |
| Premenstrual Syndrome Medicine Market Ge... | 8:25 AM |
| With the slowdown in world economic growth, the Premenstrual Syndrome Medicine Industry has also suffered a certain impact, but still maintained a rel... | |
| Methadone Hydrochloride Market - Revolut... | 4:34 AM |
| Global Methadone Hydrochloride Market ??? Overview Methadone, a synthetic narcotic analgesic, is part of a category called opioids. This opioid has ph... | |
| Bulimia Nervosa Treatment Market - Sophi... | 4:29 AM |
| Global Bulimia Nervosa Treatment Market: Overview Bulimia nervosa refers to a type of eating disorder linked with binge eating following compensatory ... | |
| Lilly Awash In Catalysts, Pipeline Updat... | 01/19/21 |
| Eli Lilly And Co (NYSE: LLY ) received an upgrade from a Mizuho Securities analyst ahead of a key data readout in March. The Lilly Analyst: Vamil Diva... | |
| Global Ethical Pharmaceuticals Market 20... | 01/19/21 |
| The Ethical Pharmaceuticals market Report deliver comprehensive analysis of the market structure along with forecast of the various segments and sub-s... | |
| STAT+: Pharmalittle: U.S. health officia... | 01/19/21 |
| U.S. officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly and Regeneron Pharmaceuticals that have been plagued by logisti... | |
| Eli Lilly tees up discovery pact worth m... | 01/19/21 |
| Under science chief Dan Skovronsky, Eli Lilly has taken some big swings at next-gen therapies, including trying to find the next big thing in oncology... | |
| Lilly gives $60M to Merus, ties in $1.6B... | 01/19/21 |
| Eli Lilly, via its Loxo Oncology biotech unit, is signing up to a three-therapy deal with Merus focused on T-cell redirecting bispecific antibody work... | |
| Lilly and Merus NV Announce Collaboratio... | 01/19/21 |
| INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Com... | |
| Diabetic Neuropathy Market In-Depth Anal... | 01/18/21 |
| Diabetic Neuropathy Market Research Report 2020 ??? This Report Is Comprised of Market Data Derived from Primary as Well As Secondary Research Techniq... | |
| Women's Health Market is Booming Worldwi... | 01/18/21 |
| Latest released the research study on Global Women???s Health Market, offers a detailed overview of the factors influencing the global business scope.... | |
| Global Biosimilars Market Opportunities ... | 01/18/21 |
| Biosimilars Market research report gives a detailed information of industry size, share, growth, segments, manufacturers, and advancements, major tren... | |
| Sickle Cell Anemia Therapeutics Market E... | 01/18/21 |
| Coherent Market Insights released a new market study on 2020-2027 Sickle Cell Anemia Therapeutics Market with 100+ market data Tables, Pie Chat, Graph... | |
| Europe and Canada are facing temporary h... | 01/15/21 |
| Summary List Placement European countries and Canada will receive fewer doses of Pfizer's coronavirus vaccine than planned in the weeks ahead, an unex... | |
| Radiopharmaceutical Market to Watch: Spo... | 01/14/21 |
| Global Radiopharmaceutical Industry Market Research Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based o... | |
| PureTech Founded Entity Follica Adds Two... | 01/14/21 |
| Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairm... | |
| Follica Adds Two Leaders in Aesthetic Me... | 01/14/21 |
| Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as Executive Chairm... | |
| Poultry Health Market SWOT Analysis By 2... | 01/13/21 |
| Poultry Health market competitive insights provide details by a competitor. Details included are market overview, company financials, revenue generate... | |
| The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... | |
| Eli Lilly and Co Stock Rises 11% as Expe... | 01/12/21 |
| Eli Lilly and Company shared the results of a trial of its Alzheimer???s drug. Following the news, Eli Lilly and Co stock soared on Monday. | |
| Biogen gets stock bump on Eli Lilly Alzh... | 01/11/21 |
| Stories you may have missed from the world of business. | |
| Twitter, Boeing fall; Eli Lilly, Crocs r... | 01/11/21 |
| Stocks that moved heavily or traded substantially Monday: Twitter, Boeing fall; Eli Lilly, Crocs rise | |
| Lilly???s preliminary Alzheimer???s data... | 01/11/21 |
| However, the read-through between Eli Lilly???s treatment, called donanemab, and Biogen's aducanumab appears tenuous. | |
| Why Eli Lilly, Exact Sciences, Biogen Ar... | 01/11/21 |
| Exact Sciences (NASDAQ: EXAS ) shares are trading higher after the company issued fourth-quarter sales guidance above analyst estimates. Exact Science... | |
| Eli Lilly Hits Record on Alzheimer's Dru... | 01/11/21 |
| https://www.investing.com/news/stock-market-news/eli-lilly-hits-record-on-alzheimers-drug-progress-2385750 | |
| STAT+: Pharmalittle: Lilly says Alzheime... | 01/11/21 |
| An experimental Eli Lilly medicine that targets beta amyloid appeared to slow the decline of patients with the early symptoms of Alzheimer???s disease... | |
| Eli Lilly Stock Gains as Drug Slows Decl... | 01/11/21 |
| The stock rose, as did shares of Biogen, which is developing a separate treatment. Lilly said its experimental drug slowed the cognitive decline of ea... | |
| Eli Lilly Surges On Positive Data From K... | 01/11/21 |
| Eli Lilly shares surged the most in six months Monday after the drugmaker said its developing Alzheimer's treatment slowed the impact of the degenerat... | |
| Lilly's stock jumps 15% after experiment... | 01/11/21 |
| Shares of Eli Lilly & Co. undefined gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease drug hel... | |
| Eli Lilly, Twitter, NIO: What to Watch W... | 01/11/21 |
| U.S. stock futures are sliding amid political risks and economic uncertainties. | |
| Buy rating | 01/19/21 |
| Mizuho upgrades from Neutral to Buy rating and raises Price Target from $164.00 to $222.00 | |
| Strong Buy rating | 12/10/20 |
| Wolfe Research upgrades from Peer Perform to Outperform rating and raises Price Target from $147.00 to $183.00 | |
| Hold rating | 11/17/20 |
| Mizuho maintains Neutral rating and lowers Price Target from $164.00 to $156.00 | |
| Buy rating | 11/10/20 |
| Bernstein initiates coverage with Market Perform rating and announces Price Target of $150.00 | |
| Strong Buy rating | 10/28/20 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $176.00 to $170.00 | |
| Buy rating | 10/23/20 |
| Truist Securities initiates coverage with Buy rating and announces Price Target of $180.00 | |
| Date | 2020-10-27 (BMO) | Est. (EPS/Rev.) | $1.71/ 5.91B |
| Actual (EPS/Rev.) | $1.54/ $5.74 B | EPS (TTM) | 6.05 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Portfolio | TraderCZ | 99.00 % | Subscribe |
| Options Eagle | George | 78.00 % | Follow |
| It's only money | Gavin wells | 58.00 % | Follow |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
